Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice

Neuron

Volumn 30, Issue 3, 2001, Pages 665-676

  Cherny, Robert A ^a   Atwood, Craig S ^b   Xilinas, Michel E ^c   Gray, Danielle N ^b   Jones, Walton D ^b   McLean, Catriona A ^a   Barnham, Kevin J ^d   Volitakis, Irene ^a   Fraser, Fiona W ^a   Kim, Young Seon ^b   Huang, Xudong ^b   Goldstein, Lee E ^b   Moir, Robert D ^b   Lim, James T ^b   Beyreuther, Konrad ^e   Zheng, Hui ^f   Tanzi, Rudolph E ^b   Masters, Colin L ^a   Bush, Ashley I ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d CSIRO   (Australia)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHELATING AGENT; CLIOQUINOL; COPPER; SYNAPTOPHYSIN; ZINC;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC ANIMAL;

EID: 0034964390     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(01)00317-8     Document Type: Article

References (49)

1. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis
2. Characterization of copper interactions with Alzheimer Aβ peptides - Identification of an attomolar affinity copper binding site on Aβ1-42
3. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
4. Neurotoxicity of halogenated hydroxyquinolines: Clinical analysis of cases reported outside Japan
5. Modulation of Aβ adhesiveness and secretase site cleavage by zinc
6. Rapid induction of Alzheimer Aβ amyloid formation by zinc
7. The possible origin of free radicals from amyloid β peptides in Alzheimer's disease
8. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion
9. Clioquinol neurotoxicity: An overview
10. Intramuscular desferrioxamine in patients with Alzheimer's disease
11. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc
12. Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease
13. Reduction of Aβ accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin
14. Amyloid-like properties of peptides flanking the epitope of amyloid precursor protein-specific monoclonal antibody 22C11
15. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
16. Zinc-induced Alzheimer's Aβ1-40 aggregation is mediated by conformational factors
17. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction
18. Cu(II) potentiation of Alzheimer Aβ neurotoxicity: Correlation with cell-free hydrogen peroxide production and metal reduction
19. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay
20. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
21. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease
22. Mass spectrophotometry of 5-chloro-7iodo-8-quinolinol metal chelates
23. Intestinal absorption and metabolism of clioquinol in the rat
24. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains
25. Comparative analysis of Aβ chemical structure and amyloid plaque morphology of transgenic mice and Alzheimer disease brains
26. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice
27. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
28. Copper, iron and zinc in Alzheimer's disease senile plaques
29. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease
30. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's Disease
31. Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis
32. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Aβ using physiological concentrations
33. Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: Nationwide survey
34. Clioquinol
35. Prophylactic value of clioquinol against travellers' diarrhea
36. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
37. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals
38. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation
39. Histological evidence implicating zinc in Alzheimer's disease
40. Biochemical evidence for the long-tail form (Aβ 1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease
41. Experimental reproduction of SMON in animals by prolonged administration of clioquinol: Clinico-pathological findings
42. Experimental studies utilizing radionuclide-labeled clioquinol as tracer in vivo
43. Neurological syndrome associated with clioquinol
44. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging
45. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
46. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice
47. Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Aβ
48. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol